On March 4, 2025, Shockwave Medical, a subsidiary of Johnson & Johnson Medical Technologies, announced the official launch of its innovative Javelin Peripheral Intravascular Lithotripsy (IVL) Catheter in the U.S. market. The introduction of this new product marks a critical step forward in addressing treatment challenges for patients with peripheral artery disease (PAD).

Javelin IVL Catheter is a solution meticulously developed by Shockwave Medical to address the treatment challenges of severe vascular calcification and extreme stenosis in PAD patients. According to Shockwave, the catheter utilizes a new non-balloon IVL platform technology designed to alter vascular calcification through shockwave lithotripsy, allowing interventional devices to smoothly pass through these difficult-to-treat stenotic areas.

The design highlight of the Javelin catheter lies in its 120-pulse shockwave lithotripsy emitter equipped at the distal end of the catheter. This emitter adopts a front-end offset design, allowing the acoustic pressure waves to diffuse spherically beyond the tip of the catheter.When the shock wave pulse is generated, a spherical energy field that extends beyond the catheter tip is formed. This energy field can closely adhere to the calcified area, enabling efficient and precise lithotripsy.

Compared with the traditional balloon-based IVL platform, the Javelin catheter has significant advantages in its design.Its spherical energy field not only gets closer to the calcified area, improving lithotripsy efficiency, but also reduces the risk of damage to surrounding normal tissues. Additionally, the Javelin catheter has a working length of 150 centimeters, providing doctors with greater operational flexibility and space.

Before its launch, the Javelin catheter has undergone rigorous clinical trial validation. Clinical trial results published by Shockwave last fall showed that the system successfully achieved its primary endpoint, demonstrating its safety and efficacy to be on par with existing catheters, and even outperforming them in certain aspects.

The success of this clinical trial not only laid a solid foundation for the promotion of the Javelin catheter but also further strengthened Shockwave Medical's leading market position in the IVL product portfolio.

Shockwave Medical's senior leadership expressed high confidence and anticipation regarding the launch of the Javelin catheter.

Former CEO Doug Godshall said of the Javelin catheter: "This catheter provides a significant alternative to the company's currently available balloon-based platforms. It transfers energy to the tip of the catheter for treating truly difficult-to-cross lesions, which will benefit a portion of PAD patients we currently cannot treat."

Dr. Nick West, the current Chief Medical Officer, emphasized: "As a pioneer in IVL technology, we are always committed to providing innovative solutions to meet the unmet needs of physicians. By listening and leveraging their valuable insights, we have developed this transformative front-end IVL platform. The Javelin catheter has a unique ability to modify calcifications and cross severely narrowed vessels, and we are proud to lead the way in offering interventional vascular physicians more flexibility to meet critical treatment needs while potentially reducing the risk of chronic limb-threatening ischemia for patients."

Following Johnson & Johnson's $13 billion acquisition of Shockwave in 2024, the launch of Shockwave Medical's Javelin IVL Catheter once again demonstrates its innovative strength and leadership in the field of biomedical engineering. This catheter not only offers new treatment options for PAD patients but also provides interventional vascular surgeons with a more efficient and safer surgical tool.

END

 

More exciting content

Welcome to follow WeChat Video Channel

Instrument Family

Related Reading

Tap for more!

 

Aohua Endoscopy Enters the Medical Robotics Field

Just now, Fresenius sold for 8.5 billion

Chongqing Alliance Collective Procurement: Chinese-produced Staplers Breakthrough, High-end Technical Indicators Become the Key to Breaking the Deadlock!

United Imaging Debuts at ECR, Digital Intelligence Technology Resonates with Green Symphony

Boston Scientific Makes a $4.4 Billion Bet on a Popular Track

Iberis® Multi-Polar Renal Artery RF Ablation Catheter System, Officially Launched for Commercialization in Europe

The Time is Ripe for China-Made Gene Sequencing! MGI Tech Collaborates with 30+ Partners to Reshape the Industry Landscape

Medtronic Partners with Philips to Tap into the Second Largest Market

Pulnovo Medical Completes the Largest Financing for Innovative Medical Devices in the Asia-Pacific Region

Single Product Sales Exceed 1 Billion in China, Hidden Leader Cuts 10% of Workforce

BusinessBusiness cooperation email: qxzj@landianyiliao.com